A key goal of geroscience research is to discover effective interventions to extend human healthspan, the years of healthy life. Currently, majority of the geroprotectors are found by testing compounds in model organisms; whether these compounds will be effective in humans is largely unknown. Here we present a novel strategy called ANDRU (aging network based drug discovery) to help the discovery of human geroprotectors. Instead of relying on model organisms, this approach is driven by human genomic and pharmacogenomic data. It first identifies human aging subnetworks that putatively function at the interface between aging and age-related diseases; it then screens for pharmacological or genetic interventions that may "reverse" the age-associated transcriptional changes seen in these subnetworks.
Introduction
Aging is a major risk factor for age-related diseases (ARDs) and the ultimate cause for most human mortalities 1 . It has been demonstrated in model organisms, that genetic, environmental, and pharmacological interventions capable of extending lifespan are associated with delayed onset and progression of multiple age-related diseases 2 . Such observations have laid the foundations for the hypothesis of geroscience 1 , which states that aging is the major modifiable risk factor for most chronic diseases, and it is possible to simultaneously prevent multiple age-related diseases by targeting the basic biology of aging.
Through drug screening and testing in model organisms, more than four hundred anti-aging drugs have been identified 3, 4 . Despite the progress, the development of human geroprotectors is facing significant Human aging is a complex process with a large number of genes and pathways being involved. For example, we and several other groups have shown that the expression of hundreds to thousands of genes can change with age in various tissues 6, 7 . To achieve a holistic understanding of the aging process and to better elucidate the complex interconnections between aging and ARDs, systems and network approaches have been explored 8, 9 . For example, Wang et al. showed that age-related disease genes were closer to aging genes in a protein-protein interaction (PPI) network 10 . We found that age-related disease categories shared functional terms including canonical aging pathways, suggesting that conserved pathways of aging might simultaneously influence multiple ARDs in humans 11 . We also developed a network algorithm called GeroNet and showed that it could prioritize biological processes mediating the connections between aging and ARDs 12 . Despite these progresses, most existing models neither considered tissue specificity nor incorporated the network dynamics associated with aging, and therefore, they captured human aging systems with rather limited accuracy. Although more recent work has started to address the tissue specificity for human aging research 13 , quantitative tissue specific aging network models are yet to be developed to allow more accurate characterization of the interplay between aging and ARDs in humans.
In addition to providing biological insights into aging and disease mechanisms, network biology can also facilitate drug discovery 14 . A promising area of development is based on the Connectivity Map (CMap) concept 15 , which uses gene expression responses to compound/gene perturbations for discovering the mode of action or drug repositioning 16 . An increasing number of studies have provided proof-of-theconcept and multiple successful applications have been reported, including a study in C. elegans to identify compounds that mimic the effect of caloric restriction to extend lifespan [17] [18] [19] .
Previously, we worked on a large human genomic dataset generated by the Gene-Tissue Expression (GTEx) project 20 . We showed that GTEx data allowed us to perform a comprehensive survey of tissuespecific aging mechanisms which recapitulated multiple hallmarks of aging 7 . In this study, we demonstrate a novel framework called ANDRU (aging network based drug discovery) to further leverage this large human dataset to identify interventions that may help to extend human healthspan.
Results

An overview of the ANDRU pipeline
ANDRU takes tissue specific transcriptomic data from humans of young and old ages as input. It outputs a list of candidate compounds or target genes that may help to slow the aging and provide geroprotection in the corresponding tissues. A network model is applied to reveal the underlying subnetworks that may function as the interface between aging and ARDs, which will be used to prioritize target genes or compounds to achieve optimized geroprotection. An overview of ANDRU is shown in Fig 1. First, for each tissue, we construct gene co-expression networks 21 from young and old tissue samples, respectively.
The subnetworks (or modules) are constructed based on correlations among gene expressions and their topological overlaps. Since subnetworks often show enrichment for specific biological functions, it provides a data-driven approach of dividing the transcriptome into multiple smaller functional modules.
Second, using aging differentially expressed genes (DEGs) and known disease gene sets, we prioritize subnetworks that are strongly influenced by both aging and diseases. Third, the aging DEGs in the prioritized subnetworks are used to query upon pharmacogenomic datasets to identify interventions that may "reverse" the age-associated expression changes in the corresponding subnetworks. The top ranked drugs or genes are further evaluated based on independent data and/or literatures.
We first applied ANDRU to subcutaneous adipose tissue samples from GTEx. Adipose is a dynamic tissue showing profound changes related to aging and can play important roles in the development of Deriving and comparing young and old adipose tissue gene co-expression networks 103 and 85 subnetworks are found in young and old adipose tissues respectively using WGCNA (weighted gene co-expression network analysis) 21 . The largest module in the old adipose is "turquoise"
(denoted hereafter as turquoise old ), which consists of 1,299 protein-coding genes (see Fig 2A) . This module is significantly enriched for "mitochondrial matrix" (FDR =1.90E-13) and "oxidoreductase" (FDR=8.34E-13) (Table S1 ). Other large modules are enriched for "cell junction", "Ubl conjugation pathway", and "signal peptide" (see details in Table S2 ). The top modules in the young adipose tissue (see Fig 2B) include "turquoise" module (1,010 protein-coding genes), which is mostly enriched for "DNA repair"; "yellow" module (939 protein-coding genes), which is mostly enriched for "WD repeat", and "magenta" module (604 protein-coding genes, denoted hereafter as magenta young ), which is mostly enriched for "mitochondrion" (Table S2 ).
Since WGCNA constructs networks from young and old samples separately, the subnetwork IDs (as color names) are assigned independently and do not match between the young and old networks. To map and compare the global network structures in young and old tissues, we considered gene overlap between the two networks. We found that turquoise old most significantly overlapped with magenta young with Jaccard index of 0.12 (see Table S3 ). Both modules are significantly enriched for mitochondria and transition peptide related functions. Since the magenta young and turquoise old show quite different sizes, this could imply that the co-expression wiring has changed substantially due to aging for genes in this subnetwork. To a further investigation, we performed a differential connectivity analysis 23 . Specifically, we aimed to identify the significant differentially co-expressed gene pairs between young and old networks. From this analysis, 1,052 significant differential co-expressions (p-value ≤ 5.0E-4) involving 643 unique genes were found ( Fig 2C. and Dataset 1). The 643 genes are significantly enriched for "oxidoreductase" (FDR of 1.66E-6), "GO:0005759~mitochondrial matrix" (FDR of 5.26E-5), and "hsa00350:tyrosine metabolism" (FDR of 6.85E-3) (Table S4 ). For these significantly changed coexpression pairs, the majority of them show gained co-expression in the old network. For example, 708
gene-gene pairs showed significant correlations in old samples but no significant correlation in young samples. In contrast, only 38 gene-gene pairs that showed significant correlation in young samples are no longer strongly correlated in old tissues (loss of correlation). For the 505 genes that are involved in the 708 gene pairs that gained correlation in old adipose (regardless of the sign of the correlation), they are enriched for "mitochondrion" (FDR = 5.2E-5), "oxidoreductase" (FDR = 3.6E-5), and "fatty acid degradation" (FDR = 4.5E-2). For the 1,052 significant differential co-expressions, majority of them show changes in their co-expression directions. For example, there are 472 negative correlations in the young samples but become positively correlated in the old samples (in the 2 nd quadrant in Fig 2C) .
Similarly, 414 positive co-expressions in the young tissues became negatively correlated in the old tissues (in the 4 th quadrant in Fig 2C) . This result indicates that substantial network re-wiring occurred in the adipose tissue during aging. The functions of the re-wired genes suggest potential link with agedependent adipose function declines in insulin sensitivity, lipolytic, and fatty acid responsiveness 24 . Since we had imbalanced number of samples for young vs. old adipose tissues, to ensure the gain of coexpression was not due to larger sample size for old adipose, we performed a down-sampling calculation.
Specifically, we randomly selected 36 samples from the old adipose tissue for 20 times, and calculated the co-expression values for the same 1,052 gene pairs. We found that the results were consistent with the ones obtained from using all the 52 old adipose samples (Dataset 1). Therefore, the gain of co-expression in the old adipose was not caused by the larger sample size.
Prioritizing subnetworks that may function at the interface between aging and age-related diseases
As co-expression network divides transcriptome into a number of non-overlapping subnetworks, it is unclear if all these subnetworks are equal with respect to aging and ARDs. Based on our previous work 12 ,
we hypothesize that subnetworks are differentially involved in aging and make unequal contribution to the development of age-related diseases. To evaluate the relative importance of each subnetwork, we considered a five-criterion evaluation and applied it to the old tissue sample derived co-expression network. We chose old network for this evaluation since in general, ARDs mainly occur in older people; therefore, modules derived from the old samples are more likely to reveal the interconnection between aging and ARDs. We describe the details of each criterion below.
Criterion 1. Enrichment for GenAge genes:
GenAge database (Build 18) contains 305 literature-based manually curated putative human aging genes 25 , and has been used as a reference aging gene list by several studies 8, 10 . We calculated the enrichment of GenAge genes for each subnetwork (see Table S5 for the results). The most significant overlap was seen in the hotpink old (p-value = 1.15E-2). This subnetwork is relatively small (107 genes) and is highly enriched for cell cycle genes (adjusted p-value = 1.3E-52).
The second most significant subnetwork was the turquoise old , which shared 34 common genes with GenAge (p-value=1.26E-2) (see Table S5 and 
Criterion 5. Enrichment for differential co-expressions:
As we have shown in the previous section, we observed profound co-expression re-wiring between magenta young and turquoise old modules. To assess the significance level of re-wiring, we performed a permutation analysis. Briefly, for a subnetwork of size n , we randomly selected n genes from all the genes in the transcriptome to form a random subnetwork.
Using the same set of young and old tissue samples, we calculated the number of significant differential co-expressions for this "random" subnetwork between young and old ages. By running this permutation test for 100 times, we estimated a p-value for observing the actual number of differentially co-expressed gene-gene pairs in our real data. Using this permutation estimation, the estimated p-value for observing 1,052 differential co-expressions was close to 0 (p <= 1E-324), which indicates that co-expression rewiring in the turquoise old module was highly significant.
To summarize, we listed the results for the top 10 modules with more than 50 protein coding genes in Table 1 (sorted based on the enrichment for differentially expressed aging genes). The turquoise old module was ranked at the 1 st position for enrichment of aging DEGs, it was also ranked at 2 nd for enrichment of GenAge genes and 1 st based on GeroNet computation. Collectively, the turquoise old stood out as a significant subnetwork in which aging and a group of metabolic diseases like type 2 diabetes are connected.
To visualize the turquoise old subnetwork, we mapped its genes onto the HPRD protein-protein interaction (PPI) network and displayed the largest connected component in Fig 
Prioritize drugs and gene targets using a network pharmacogenomic approach
An important goal of human aging and geroscience research is to discover effective interventions to slow aging and delay the onset of age-related diseases. As our analysis first prioritizes aging subnetworks that are closely related to diseases, the next step is to identify drugs or target genes that may reverse the changes in the prioritized subnetworks. To achieve this goal, we adopt a network pharmacogenomic approach based on the concept of connectivity maps ( For our study, we hypothesize that if a drug or gene perturbation could reverse aging DEGs in our prioritized aging subnetworks, then this drug/gene is likely to be geroprotective. To implement this approach, we divided the 265 differential genes into 148 up-regulated genes and 117 down-regulated genes (Table S7 ) and use them to query the drug/gene perturbation databases. The up-regulated aging genes were mostly enriched for "extracellular matrix" with FDR 6.7E-6 and the down-regulated aging genes were mostly enriched for "transmembrane" with FDR 1.48E-3.
We relied on CREEDS database which is a manually curated list of 4,295 single-drug perturbations and Top drugs based on differential aging genes: We list the top 5 identified drugs (among 4,295) in Table 2 .
It is of note that same drugs may appear more than once. This happens when the top signatures from different experiments tested the same drugs, or when the top signatures were from the same drug 1 0 CREEDS. We include metformin as a reference due to its therapeutic applications in multiple disease areas. Due to its robust record of safety, metformin is among the top candidate human geroprotectors that have been cleared by FDA to enter clinical trials 33 .
As Table 2 shows, several conjugated linoleic acid (CLA) induced gene expression signatures were ranked at the top. These signatures were derived from a study investigating the effect of CLA supplementation on gene expression in human adipose tissue biopsies (GSE16615) 34 . From the enrichment analysis, both isomers of CLA, either cis-9, trans-11 CLA or trans-10, cis-12 CLA, or their mixture up-regulated the expression of multiple genes that were down-regulated in the old GTEx adipose 
Discussions
In this work, we demonstrated a novel informatics pipeline − ANDRU to construct human aging network and identify interventions that can be geroprotective. We applied ANDRU to GTEx adipose and artery tissues. With aging, adipose tissue undergoes significant changes and contributes to the development of insulin resistance, metabolic dysfunction, inflammation, and impaired regenerative capacity 22 . From more than eighty adipose subnetworks, we prioritized and highlighted the turquoise old for its putative role as the interface between aging and several ARDs. Since different subnetworks often have distinct functions and show differential connections to various diseases, our approach provides the option to reverse the aging in different subnetworks to address different types of diseases (e.g., the inflammation related diseases vs.
metabolic related diseases). Since the diseases of concern often vary among individuals, the option of providing prioritization based on aging subnetworks considering individual's genetic and genomic profiles could facilitate personalized geroprotection in future.
The importance and feasibility of performing in silico drug screening for geroprotection has been first demonstrated by Zhavoronkov et al. followed by some experimental validations 48 . Our method is conceptual similarity to their method but has a very different way of implementation. For example, we relied on a de novo network construction approach to build aging networks while GeroScope used by Zhavoronkov et al. considered prior knowledge of known aging pathways. While both approaches considered age-related transcriptional changes, the input dataset and methods used to incorporate such information were different. Therefore, our approach represents a significant alternative option for performing in silico geroprotector discovery.
The current implementation of ANDRU has its limitations and will require future improvement. First, as we relied on existing gene expression signature databases, we are limited to the perturbations collected by these databases and important genes or drugs could be missed if the data was not generated or not included into the database. Although this "incompleteness" of perturbation signatures will likely persist in the near future, perturbation datasets are continuing to grow. For example, the NIH LINCS project is generating high throughput perturbation expression signature data at very large scale 31 , making it another useful resource for the network pharmacogenomics development. Second, CREEDS contains data collected from multiple species, and the non-human data or data obtained from different tissue types could cause either false positive or false negative hits. This would require additional conformational experiments to ensure perturbation signatures are reproducible in the desirable tissue types.
Finally, in this pilot work, we considered only two tissue types to illustrate the pipeline. From these two tissues, ANDRU output different drug/gene candidates. This suggests that to achieve optimized systemic geroprotection, combining several drugs should be something for consideration. As GTEx profiles more than 50 tissue types, it is a future work to investigate aging networks and search for geroprotectors at a "whole-body" scale. With an unprecedented increasing amount of human omics data, we believe that integrating them to refine the aging networks, and leveraging them to search for the most effective human geroprotectors represents a promising strategy to speed up the geroscience research.
Experimental Procedures Data collection and processing
Human gene expression data (both fpkm and raw reads count) is from GTEx portal 20 . We divided individuals into three groups according to their chronological ages: young group (age <=35), old group (age >=65), and those in between. We only considered young and old groups for further analysis. We performed a few data processing steps to require genes to have at least 0.1 RPKM in 2 or more individuals followed by a quantile normalization across genes. Following GTEx study 20 , we adjusted the following confounding factors: (1) gender, (2) collection center, (3) RIN, (4) ischemic time, and (5) 3 genotype principal components. The genotype PCs were constructed using GCTA 49 with several quality control steps using plink (e.g., --MAF 0.1, --geno 0.05, --hwe 1e-6, --Chr 1-22).
Construction of young and old gene co-expression networks
For both young and old samples, the expression values for each gene were quantile normalized into a standard normal distribution. We then removed sample outliers by a hierarchical clustering of the samples based on the expression data for young and old groups respectively. 36 samples in young and 52 samples in old group for adipose tissue and 34 samples in young and 33 samples in old for artery aorta were kept to construct young and old networks by weighted gene correlation network analysis (WGCNA) 21 . We set the soft power to be 5 for adipose and 4 for artery aorta, respectively.
Differential gene expression and differential connectivity analysis
We collected the read counts for young and old samples separately and applied two pipelines 
Contributions
ZT conceived the concept of the work. JY and ZT performed the analysis. JY, SH, YS, ZT wrote the manuscript. All authors helped to discuss and improve the work.
Competing Interests
The authors have declared no competing interests. A T 3  2  2  ,  2  2  3  -2  3  2 , 
References
) . 5 K u m a r , S . & L o m b a r d , D . B . F i n d i n g P o n c e d e L e o n ' s P i l l : C h a l l e n g e s i n S c r e e n i n g f o r A n t i - A g i n g M o l e cn e t w o r k p h a r m a c o l o g y a p p r o a c h r e v e a l s n e w c a n d i d a t e c a l o r i c r e s t r i c t i o n m i m e t i c s i n C . e l e g a n s . A g i n g C e l l 1 5 , 2 5 6 -2 6 6 , d o i : 1 0 . 1 1 1 1 / a c e l . 1 2 4 3 2 ( 2 0 1 6 ) . 2 0 T h e G T E x C o n s o r t i u m . T h e G e n o t y p e -T i s s u e E x p r e s s i o n ( G T E x ) p i l o t a n a l y s i s : M u l t i t i s s u e g e n e r e g u l a t i o n i n h u m a n s . S c i e n c e 3 4 8 , 6 4 8 -6 6 0 , d o i : 1 0 . 1 1 2 6 / s c i e n c e . 1 2 6 2 1 1 0 (2 0 1 5 ) . 2 1 Z h a n g , B . & H o r v a t h , S . A g e ne r a l f r a m e w o r k f o r w e i g h t e d g e n e c o -e x p r e s s i o n n e t w o r k a n a l y si s . S t a t A p p l G e n e t M o B 4 ( 2 0 0 5 ) . 2 2 P a l m e r , A . K . & K i r k l a n d , J . L . A g i n g a n d a d i p os e t i s s u e : p o t e n t i a l i n t e r v e n t i o n s f o r d i a b e t e s a n d r e g e n e r a t i v e m e d i c i n e . E x p e r i m e n t a l g e r o n t o l o g y 8 6 , 9 7 -1 0 5 , d o i : 1 0 . 1 0 1 6 / j . e x g e r . 2 0 16 . 0 2 . 0 1 3 ( 2 0 1 6 ) . 2 3 M c K e n z i e , A . T . , K a t s y v , I . , S o n g , W . M . , W a n g , M . H . & Z h a n g , B . D G C A : A co m p r e h e n s i v e R p a c k a g e f o r D i f f e r e n t i a l G e n e C o r r e l a t ih e C o - f a c t o r o f L I M D o m a i n s ( C L I M / L D B / N L I ) M a i n t a i n s B ad o i : 1 0 . 1 0 1 6 / j . b b r . 2 0 1 6 . 0 5 . 0 1 2 ( 2 0 1 7 ) . 4 5 S h e n , L . R . , P a r n e l l , L . D . , O r d o v a s , J . M . & L a i , C . Q . C u r c u m i n a n d a g i n g . B i
